Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine or Decitabine in Treatment-Naive AML
NCT02203773Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Oct 2014
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of venetoclax in acute myeloid leukemia (AML) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Adverse Events at 1 year, Maximum observed plasma concentration at 5 days and 8 more. Started Oct 2014; status: terminated.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02203773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203773.